Fibrinogen Plasma Levels as a Marker of Thrombin Activation: New Insights on the Role of Fibrinogen as a Cardiovascular Risk Factor

Summary

Fibrinogen has recently emerged as a major risk factor for athero- thrombosis. However, the pathophysiologic mechanism linking high fibrinogen concentration to cardiovascular disease is unclear.

In this study 136 subjects (75 males, 61 females, age 51.7 ± 14.4 years, mean ± standard deviation, range 17-82) were tested for total and HDL-cholesterol, total triglycerides, apolipoprotein AI, apolipo- protein B, fibrinogen, prothrombin fragment and D-dimer. Moreover, 5 subjects who had hyperfibrinogenemia (range 450 to 950 mg/dl) for at least 6 months by repeated measurements, were treated with a short 7-day course of heparin 12,500 U/day subcutaneously. The effect of heparin on all the above mentioned parameters was observed at the end of treatment and after 7 days of wash-out. Simple regression analysis detected a positive correlation between fibrinogen and age, prothrombin fragment and D-dimer, and a negative correlation between fibrinogen and HDL-cholesterol and apolipoprotein AI. A direct correlation between age and both prothrombin fragment and D-dimer was also demonstrated. Multivariate analysis showed a persistent correlation between fibrinogen and prothrombin fragment, D-dimer and age, that was not influenced by sex, smoking habit and body mass index. In the 5 hyperfibrinogenemic subjects, heparin administration significantly reduced fibrinogen (625.4 ± 211.1 vs 455.2 ± 112.3 mg/dl, p <0.03), prothrombin fragment (0.97 ± 0.1 vs 0.63 ± 0.2 nM, p <0.002) and D-dimer (336 ± 101.8 vs 275.2 ± 78.5 ng/ml, p <0.03). All these parameters returned to baseline after 7 days of wash-out (fibrinogen 632.5 ± 198.2 mg/dl, prothrombin fragment 0.96 ± 0.2 nM, D-dimer 325.8 ±98.65 ng/ml).

These data indicate that fibrinogen plasma levels are strongly correlated to parameters of thrombin activation in plasma and suggest that high fibrinogen plasma levels might be a risk marker for cardiovascular disease because expression of an existing thrombophilia.

• References

• 1 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 2 Kannel WB, Wolf PA, Castelli WP. et al. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987; 258: 1183-1186
• 3 Theroux P, Latour JG, Leger-Gauthier C. et al. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987; 75: 156-162
• 4 Kruskal JB, Commerford PJ, Franks JJ. et al Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-1365
• 5 Aronson DL, Stevan L, ball AP, Franza BR Jr, Finlayson JS. Generation of the combined prothrombin activation peptide (FI.2) during the clotting of blood and plasma. J Clin Invest 1977; 60: 1410-8
• 6 Graeff H, Hafter R. Detection and relevance of cross linked fibrin derivatives in blood. Sem Thromb Hemost 1982; 8: 57-68
• 7 Bachorik PS, Kwiterovich PO. Measurement of plasma cholesterol low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. In: Techniques in diagnostic human biochemical genetics. A laboratory manual Hommes FA. ed. New York: Wiley-Liss; 1991: 425-459
• 8 Friedewald WT, Lewy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
• 9 Rossi E, Mondonico P, Lombardi A, Preda L. Method for determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988; 52: 453-468
• 10 Abbate R, Priscp D, Rostagno C, Boddi M, Gensini GF. Age-related changes in the hemostatic system. Int J Clin Lab Res 1993; 23: 1-3
• 11 Nossel HL, Yudelman J, Can field RE. et al. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 12 Gensini GF, Prisco D, Lamberti R. et al. Effective control of the elevated plasma fibrinogen levels by low dose heparin. Fibrinolysis 1990; 4 (Suppl 1) 78 Abstract
• 13 Franks JJ, Kirsch RE, Frith LOC. et al. Effect of fibrinogenolytic products D and E on fibrinogen and albumin synthesis in the rat. J Clin Invest 1981; 67: 575-580
• 14 Mitropoulos KA, Esnouf MP. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. Thromb Res 1990; 57: 541-559